DRKS00017688
尚未招募
未知
A placebo-controlled, randomized, double-blind study to assess the efficacy of a specific probiotic formulation in the reduction of recurrent respiratory tract infections (RTIs) and antibiotic prescriptions - MIC01-RTI
Microbiotica GmbH0 个研究点目标入组 354 人2019年9月12日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- recurrent respiratory tract infectionsICD-10: J00-J22
- 发起方
- Microbiotica GmbH
- 入组人数
- 354
- 状态
- 尚未招募
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Age 18 and older
- •Patients starting antibiotic treatment (oral or i.v.) for any cause for not more than 14 days
- •Patients with a history of 2\-4 episodes of RTI during the last 12 months before inclusion
- •Patients with a history of 1\-4 antibiotic therapies (oral or i.v.) for any cause during the last 12 months before inclusion
- •Patients able to understand and follow study procedures
- •Signed Informed Consent Form
排除标准
- •Acute and chronic diarrhea at inclusion
- •People who never had a flu vaccination before, but had one for the period covering the study duration (autumn/winter 2019/2020\) or are planning a vaccination for this period.
- •Intake of probiotic supplements and/or medications 4 weeks prior and/or during the study
- •Severe COPD (GOLD grade IV or group D)
- •Severe asthma (eosinophilic or asthma, treated with monoclonal antibodies)
- •Immunodeficiency (e.g. HIV, chemo\-, radio\- , immune therapy) in the last 12 months or during the study
- •Long term use of immune suppressant or immune stimulating prescription medication (e.g. interferon, growth factor, monoclonal antibodies, etc.)
- •Subjects presenting with an active, non\-controlled intestinal disease such as Crohn’s disease or ulcerative colitis
- •A previous documented C. difficile infection \<3 months prior to study initiation
- •Severe organ or systemic disease which will influence the conduct of the study based on the physician´s assessment as well as any health condition that will not allow to follow study procedures or compliance
结局指标
主要结局
未指定
相似试验
招募中
1 期
Clinical study of Cistanche herb extract for cervical spondylotic myelopathyCervical spondylotic myelopathyJPRN-jRCTs041200080Kawaguchi Yoshiharu50
进行中（未招募）
1 期
A study to evaluate safety and efficacy of APO-2 at three different doses in patients with diabetic foot ulcerDiabetic Foot UlcerMedDRA version: 24.0Level: LLTClassification code 10012664Term: Diabetic foot ulcerSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-001653-27-CZAposcience AG120
进行中（未招募）
1 期
Study to assess the safety and efficacy of PCN-101 in treatment-resistant depressioTreatment-resistant depressionMedDRA version: 20.0Level: PTClassification code 10012378Term: DepressionSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-005457-25-PLPerception Neuroscience, Inc93
进行中（未招募）
1 期
A study to evaluate safety and efficacy of APO-2 at three different doses in patients with diabetic foot ulcerEUCTR2018-001653-27-DEAposcience AG132
进行中（未招募）
1 期
Investigation of efficacy of Secukinumab in patients with moderate to serve atopic dermatitisModerate to serve atopic dermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-005181-57-DEGWT-TUD GmbH45